Tafalgie Therapeutics

Phase 1

Your browser does not support HTML5 video. A new pharmaceutical approach to treating pain Towards a safe and effective alternative to existing painkillers. Our molecule Tafalgie Therapeutics, a CNRS spin-off, is a clinical-stage biotechnology company specializing in the development of next-generation painkillers The company is pioneering the development of a new therapeutic class of non-opioid […]

About

Your browser does not support HTML5 video. A new pharmaceutical approach to treating pain Towards a safe and effective alternative to existing painkillers. Our molecule Tafalgie Therapeutics, a CNRS spin-off, is a clinical-stage biotechnology company specializing in the development of next-generation painkillers The company is pioneering the development of a new therapeutic class of non-opioid […]

Company Info

TypePrivate

LocationFrance

StagePhase 1

Contact

Sectors

Small Molecule Drugs

SIMILAR COMPANIES

Phase 2 · Lille

Pre-clinical · Lyon

ABL Diagnostics

Pre-clinical · Strasbourg

Acticor Biotech

Pre-clinical · Paris

Pre-clinical · Lyon

Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.